Provided by Tiger Fintech (Singapore) Pte. Ltd.

Recursion Pharmaceuticals, Inc.

5.38
-0.1223-2.22%
Volume:10.36M
Turnover:56.17M
Market Cap:2.16B
PE:-3.18
High:5.65
Open:5.35
Low:5.28
Close:5.50
Loading ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal

Simply Wall St.
·
19 Apr

BRIEF-Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data

Reuters
·
16 Apr

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

PR Newswire
·
16 Apr

Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?

Insider Monkey
·
15 Apr

Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today

TIPRANKS
·
15 Apr

Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”

Insider Monkey
·
15 Apr

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?

Zacks
·
14 Apr

Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)

TIPRANKS
·
13 Apr

Recursion Pharmaceuticals call volume above normal and directionally bullish

TIPRANKS
·
12 Apr

Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing

THOMSON REUTERS
·
11 Apr

Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%

THOMSON REUTERS
·
11 Apr

AI Biotech Stocks Shined. Recursion Soared 20% And Absci Surged 13%

Tiger Newspress
·
11 Apr

US FDA to Phase Out Animal Testing in Drug Development, Adopt AI Methods

Reuters
·
11 Apr

Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
11 Apr

Recursion Pharmaceuticals price target lowered to $8 from $10 at Morgan Stanley

TIPRANKS
·
10 Apr

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

GlobeNewswire
·
09 Apr

Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment

MT Newswires Live
·
08 Apr

Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham

Dow Jones
·
08 Apr

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of Rec-3565, a Selective Malt1 Inhibitor for Relapsed or Refractory B-Cell Lymphomas

THOMSON REUTERS
·
08 Apr

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

GlobeNewswire
·
08 Apr